About Enumera Molecular
Enumera Molecular is a company based in Ann Arbor (United States) founded in 2022.. Enumera Molecular has raised $18.72 million across 1 funding round from investors including Arboretum Ventures. Enumera Molecular offers products and services including EnumeraPlex. Enumera Molecular operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Ann Arbor, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$18.72 M (USD)
in 1 rounds
-
Latest Funding Round
$18.72 M (USD), Series A
May 05, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enumera Molecular
Enumera Molecular offers a comprehensive portfolio of products and services, including EnumeraPlex. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for simplified, rapid molecular counting in clinical diagnostics and genomics.
Funding Insights of Enumera Molecular
Enumera Molecular has successfully raised a total of $18.72M through 1 strategic funding round. The most recent funding activity was a Series A round of $18.72 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $18.7M
-
First Round
First Round
(05 May 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2022 | Amount | Series A - Enumera Molecular | Valuation | Arboretum Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enumera Molecular
Enumera Molecular has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Arboretum Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enumera Molecular
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enumera Molecular
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enumera Molecular Comparisons
Competitors of Enumera Molecular
Enumera Molecular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enumera Molecular
Frequently Asked Questions about Enumera Molecular
When was Enumera Molecular founded?
Enumera Molecular was founded in 2022.
Where is Enumera Molecular located?
Enumera Molecular is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Who is the current CEO of Enumera Molecular?
Matthew Cooper is the current CEO of Enumera Molecular.
Is Enumera Molecular a funded company?
Enumera Molecular is a funded company, having raised a total of $18.72M across 1 funding round to date. The company's 1st funding round was a Series A of $18.72M, raised on May 05, 2022.
What does Enumera Molecular do?
Enumera Molecular was founded in 2022 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where liquid biopsy tools are manufactured to enable the assessment of biomolecules. Rapid and low-cost solutions are facilitated through these tools, supporting diagnostic applications in clinical and research settings. The companys efforts center on advancing non-invasive biomolecule analysis methods.
Who are the top competitors of Enumera Molecular?
Enumera Molecular's top competitors include Guardant Health, Foundation Medicine and Natera.
What products or services does Enumera Molecular offer?
Enumera Molecular offers EnumeraPlex.
Who are Enumera Molecular's investors?
Enumera Molecular has 1 investor. Key investors include Arboretum Ventures.